期刊文献+

PCR-反向点杂交法检测乙型肝炎病毒的基因耐药变异与基因分型 被引量:5

下载PDF
导出
摘要 目的探讨PCR-反向点杂交法用于检测HBV基因耐药变异与基因分型的可行性。方法采用PCR-反向点杂交法对89例慢性乙型肝炎患者的血清标本进行HBV基因耐药变异和基因分型检测;用DNA测序法对患者的HBV DNA进行测序,确定HBV的耐药变异与基因分型情况,评价PCR-反向点杂交法的准确性、灵敏度及临床应用价值。结果 89例标本经PCR-反向点杂交法检出变异株31例,其中rtL180M+rtM204V联合突变株15例,rtN236T突变株4例,rtM204I突变株9例,rtA181V突变株3例;野生株55例,阴性标本3例;HBV基因型中C基因型72例,B基因型14例。经测序确定PCR-反向点杂交法检测准确度、特异度均为100%。结论采用PCR-反向点杂交法检测HBV基因耐药变异与基因分型可靠、简便、经济、高效,适宜临床推广。
出处 《山东医药》 CAS 2013年第25期51-53,共3页 Shandong Medical Journal
  • 相关文献

参考文献12

  • 1Chen CH, Lee CM, Hung CH, et al. Clinical significance and evo- lution of core promoter and precore mutations in HBeAg-positive pa- tients with HBV genotype B and C: a longitudinal study[ J ]. Liver Int, 2007,27(6) :806,815.
  • 2Kobayashi M, Suzuki F, Akuta N, et al. Response to long-term lamivudine treatment in patients infected with hepatitis B virus geno- types A, B, and C[J]. J Med Virol, 2006,78(10) :1276-1283.
  • 3中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量:14010
  • 4刘伟,李代红.慢性乙型肝炎拉米夫定治疗后病毒基因变异的分析[J].中国现代医学杂志,2010,20(21):3350-3353. 被引量:3
  • 5Tong MJ, Blatt LM, Kao JH, et al. Basal core promoter T1762/ A1764 and precore A1896 gene mutations in hepatitis B surface an- tigen-positive hepatocellular carcinoma: a comparsion with chronic carriers[ J]. Liver Int, 2007,27 (10) : 1356-1363.
  • 6Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutant s and the risk of hepatocellular carcino- ma[J]. J Natl Cancer Inst, 2008,100(16) :1134-1143.
  • 7王程,孙剑,陈金军,王战会,侯金林.拉米夫定耐药慢性乙型肝炎患者HBV P基因区突变序列分析[J].南方医科大学学报,2008,28(5):729-730. 被引量:12
  • 8肖宏,王冯滨,徐俊,高涛.HBV变异的检测及临床[J].中国免疫学杂志,2002,18(5):366-368. 被引量:5
  • 9戴晨阳,刘丽,梁树人,李秀梅,徐健.658例乙型肝炎患者HBV多位点耐药基因检测结果分析[J].山东医药,2012,52(7):56-58. 被引量:15
  • 10Keeffe EE, Dieterich ED, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States[J]. Clin Gastroenterol Hepatol, 2008,6(12) :1315-1341.

二级参考文献32

  • 1王虹,姚光弼.慢性乙型肝炎T淋巴细胞的肝内浸润与肝损伤的关系[J].上海免疫学杂志,1993,13(3):140-142. 被引量:13
  • 2李晶,刘兴祥.慢性乙型肝炎患者HBV-DNA载量与拉米夫定疗效及YMDD变异相关性研究[J].医学理论与实践,2006,19(12):1387-1388. 被引量:2
  • 3Yatsuji H,Noguchi C,Hiraga N,et al.Emergence of a novel lami-vudine-resistant hepatitis B virus variant with a substitution outsidethe YMDD motif[J].Antimicrob Agents Chemother,2006,50(11):3867-3874.
  • 4Schildgen O,Sirma H,Funk A,et al.Variant of hepatitis B viruswith primary resistance to adefovir[J].N Engl J Med,2006,354(17):1807-1812.
  • 5Lai CL,Leung N,Ten EK,et al.A l-year trial of telbivudine,lami-vudine,and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B[J].Gastroenterology,2005,129(2):528-536.
  • 6Allen MI,Deslauriers M,Andrews CW,et al.Identification andcharacterization of mutations in hepatitis B virus resistant to lamivu-dine.Lamivudine Clinical Investigation Group[J].Hepatology,1998,27(6):1670-1677.
  • 7Lok AS,Zoulim F,Locarnini S,et al.Antiviral drug-resistant HBVstandardization of nomenclature and assays and recommendations formanagement[J].Hepatology,2007,46(1):254-265.
  • 8Hadziyannis SJ,Tassopoulos NC,Heathcote EJ,et al.Adefovirdipivoxil for the treatment of hepatitis B e antigen-negative chronichepatitis B[J].N Engl J Med,2003,348(9):800-807.
  • 9Schiff ER,Lai CL,Hadziyannis S,et al.Adefovir dipivoxil therapyfor amivudine-resistant hepatitis B in pre-and post-liver transplanta-tion patients[J].Hepatology,2003,38(6):1419-1427.
  • 10Warner N,Locarnini S.The antiviral drug selected hepatitis B virusrtAl81T/sWl72*mutant has a dominant negative secretion defectand alters the typical profile of viral rebound[J].Hepatology,2008,48(1):88-98.

共引文献14037

同被引文献39

引证文献5

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部